The mastery and foresight to take your biologic further
Large molecule drugs, or biologics, offer innovative and targeted treatment options for a variety of diseases, including rare cancers, autoimmune disorders, and genetic conditions. But developing and manufacturing large molecule drugs at scale for patients worldwide is a complex undertaking — one that requires industry-leading capabilities and expertise, bonded by key elements such as mastery and foresight.
At Thermo Fisher Scientific, we’ve carefully cultivated these skills through our contract development and manufacturing solutions that meet the unique needs of today’s drug developers, and we’ve collaborated on over 240+ biologic programs so far. Our scientific and technical expertise is unmatched, and we’re excited to showcase our services at BIO 2024.
Please fill out the form below, including the topic you are interested in, and we will be in touch.
About BIO 2024
The 2024 BIO International Convention is the largest and most comprehensive event for the global biotechnology sector, representing the full ecosystem of biotech by converging over 20,000 industry leaders and experts from around the world.
Whether you work at a public pharma company, biotech startup, academic institution, non-profit, or government, or are a researcher, business development professional, or investor, BIO is where you'll make valuable connections and build relationships.
Attend our session
Sponsored panel discussion: Agile biologics development and manufacturing strategies to meet market demand
Date/Time: Monday, June 3, 4:15 p.m. – 5:15 p.m. PDT
Abstract: The biomanufacturing landscape faces complex challenges in aligning biologic therapy development and supply with rapidly changing market dynamics. Innovations in therapies, the need to respond to global health crises, and shifts in treatment approaches profoundly impact product mix and volume requirements.
Biomanufacturing facilities must adapt to produce a broad range of products with varied volume demands, from mass-produced vaccines to personalized medicines. This shift challenges operational capabilities and necessitates innovations in supply chain management, quality assurance, and regulatory compliance to handle the complexity and variability of product portfolios effectively.
This panel will draw on the expertise of industry professionals to discuss strategies for maintaining agility and responsiveness in biomanufacturing. Topics will cover the critical importance of agility in this domain, methods for enhancing it, and real-world examples of its impact on success. Attendees will gain insight into how to harness agility to manage complexities and improve operational efficiency across the biomanufacturing value chain.
Meet with our team
Meet with Thermo Fisher Scientific’s experts at BIO 2024 to explore our comprehensive global clinical supply solutions and discover how our end-to-end, integrated CDMO services and solutions can support your unique clinical trial needs.
To schedule a private meeting with our team during the show, click below.